Here's a reminder of the 2023 Poster Presentations:


A01: Primary Human Immune Cell Assays for the Evaluation of New Immuno-Oncology Therapies, Presented by Robert B., Antibody Analytics

A02: Design of a Next-Generation Drug Delivery System for Selective Targeting of Tumour Associated Macrophages, Presented by Eva S., AstraZeneca

A03: Multifuncional Anticancer Activity of VLPs Harboring CD40L, Presented by Isadora S., Brazilian Biosciences National Laboratory (LNBio-CNPEM)

A04: Modulation of Cytokine Secretion and Macrophage Differentiation in a 3D Heterotypic Spheroid Model of Colon Cancer, Presented by Cordula T., Charles River Laboratories Germany GmbH

A05: LAL-Deficiency Induced Myeloid-Derived Suppressor Cells as Biomarkers and Targets for Lung Cancer, Presented by Hong D., Indiana University

A06: Lysosomal Acid Lipase Determines Functions of CD11c+ Myeloid-Derived Suppressor Cells, Presented by Cong Y., Indiana University

A07: Macrophage Condition Supernatants Can Drive EMT Not Just via TGF-β Signalling, Presented by Darryl T., Concept Life Sciences

A08: Novel A20 Based Therapeutic Strategies to Fight Lung Cancer, Presented by Monika H., Medical University of Vienna

A09: Collagen Fragments as Biomarkers for Prediction and Pharmaco-Dynamics in Cancer Immunotherapy, Presented by Neel N., Nordic Bioscience

A10: Multabodies: Revolutionizing Antibody Therapeutics, Presented by Joanne H., Radiant Biotherapeutics

A11: Targeting Cancer Using Super Activated Killer T Cells (SAK-T), Presented by Dikla BA., Sakura Bio

A12: A Luciferase-Based Method to Assess Antigen-Specific T Cell Responses and Antigen Presentation for the In Vitro Evaluation of Immunomodulatory Checkpoints and Therapeutics, Presented by Jimena AF., University Medical Center Groningen

A13: Selective Blockade of CD47-SIRP Alpha “Don’t Eat Me” Signaling with a Her2-CD47 Bispecific Antibody-Derivative, Presented by Yuzhu Q., University Medical Center Groningen

A14: Healing the Wound that Is Pediatric Ependymoma, Presented by Andrea G., University of Colorado

A15: Expression of Antigen Processing Machinery is Associated with Survival Outcomes in Oesophageal Adenocarcinoma, Presented by William P., University of Southampton

A16: Efficacy of Anti-PD-1 Immunotherapy in a Pre-Clinical Breast Cancer Model in the Context of Obesity and Weight Loss, Presented by Elysa W., Vanderbilt University

A17: A Novel Trispecific Antibody Targeting EGFR/PD-L1/VEGFa, Presented by Peipei Z., Sanyou Biopharmaceuticals Co., Ltd.




B01: Identifying T-Cell Engagers with Optimal Potency and Cytokine Release Profiles with Differentiated and Developable CD3-Binding Antibodies, Presented by Wendy B., AbCellera

B02: Development of a Method to Generate Bispecific Antibodies In Vitro Based on an Intein-Based Protein Splicing Reaction, Presented by Yeaji L., Ajou University

B03: Quantification of the Antigen Density Activation Threshold for Targeted Immunotherapeutics, Presented by Adele H., Antibody Analytics

B04: YH013, a Common Light Chain Bispecific ADC Targeting EGFR and MET, Improves Preclinical Efficacy Over Its Parental Single-Targeting ADCs, Presented by Jie H., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

B05: Development of High Throughput Single-B Cell Antibody Discovery Platform, Presented by Boris X., Biointron Biological, Inc.

B06: Investigating the In Vitro Enhancement of Differential Immune Cell Responses by Immunotherapies Pembrolizumab, Blinatumomab and Trastuzumab, Presented by Omar Q., Celentyx Ltd.

B07: Herpesvirus Entry Mediator (HVEM) as a Novel Therapeutic Target in Multiple Myeloma, Presented by Flavia P., City of Hope

B08: The OMNI CRISPR Nuclease Panel: Making Any Gene Targetable, Presented by Tali PJ., Emendo Bio, Inc.

B09: Commensal-Derived Antigens Can Drive an Efficient T Cell Response Against Selected TAAs, Presented by Jean-Marie C., Enterome SA

B10: Incorporation of TRDV Segments into TCR Alpha Chains, Presented by Elham F., Helmholtz Institute for Translational Oncology

B11: Patient-Derived Organoids: A Powerful Preclinical Platform for De-Risking Immuno-Oncology Therapies, Presented by Farzin P., HUB Organoids

B12: A Novel In Vivo Model to Simultaneously Assess Efficacy and Toxicity of Chimeric Antigen Receptor T-Cell Immunotherapy, Presented by Philip G., Jackson Laboratory

B13: Characterisation of Endometrial Tumour Infiltrating Lymphocytes: Investigating Their Phenotype, Presented by Balkese A., King Abdullah International Medical Research Centre

B14: Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Toward Multiple Myeloma, Presented by Kim Anh G., KTH Royal Institute of Technology

B15: Site-Specific Photoaffinity Labeling for the Preparation of Radioimmunoconjugates, Presented by Abel N., KTH Royal Institute of Technology

B16: Fc Effector Function Assay Development, Presented by Juliet C., LifeArc

B17: Considerations Regarding Cellular Starting Materials for Cell-Based Immunotherapies, Presented by Enric R., Minaris Regenerative Medicine

B18: A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies, Presented by Francesca R., Novartis Institutes for Biomedical Research


Additional Virtual Posters

V1: Using Ehrlich Cell Line-Derived Proteoglycan Antigen as Antitumor Vaccine Candidate, Presented by Pablo M., IdiPAZ - La Paz University Hospital

B19: Chlorotoxin Analogue Targeted CAR-T Therapy Against GBM (Glioblastoma Multiforme)Presented by Anna H., Pazmány Péter Catholic University 



Register Now

Modulating the Tumour Microenvironment